Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

Condition:   Cutaneous Squamous Cell Carcinoma in Situ (CSCCis) Interventions:   Drug: Cutaneous Cream application;   Drug: Placebo Cutaneous Cream application Sponsor:   Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials